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ABSTRACT 
BRAFV600E mutations occur in 10% of colorectal cancer (CRC) cases, are associated with 
poor survival and have limited responses to BRAF/MEK inhibition with or without EGFR 
inhibition. There is an unmet need to understand the biology of poor prognostic BRAFMT 
CRC. We have used differential gene expression and pathway analyses of untreated stage II 
and stage III BRAFMT (discovery set: n=31; validation set: n=26) CRC and an siRNA screen 
to characterize the biology underpinning the BRAFMT subgroup with poorest outcome. 
These analyses identified the unfolded protein response (UPR) as a novel and druggable 
pathway associated with the BRAFMT CRC subgroup with poorest outcome. We also found 
that oncogenic BRAF drives endoplasmic reticulum (ER) stress and unfolded protein 
response (UPR) pathway activation through MEK/ERK. Furthermore, inhibition of GRP78, 
the master regulator of the UPR, using siRNA or small molecule inhibition, resulted in acute 
ER stress and apoptosis, in particular in BRAFMT CRC cells. In addition, dual targeting of 
protein degradation using combined Carfilzomib (proteasome inhibitor) and ACY-1215 
(HDAC6-selective inhibitor) treatment resulted in marked accumulation of protein 
aggregates, acute ER stress, apoptosis and therapeutic efficacy in BRAFMT in vitro and 
xenograft models. Mechanistically, we found that the apoptosis following combined 
Carfilzomib/ACY-1215 treatment is mediated through increased CHOP expression. Taken 
together, our findings indicate that oncogenic BRAF induces chronic ER stress and that 
inducers of acute ER stress could be a novel treatment strategy for poor prognostic 
BRAFMT CRC. 
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INTRODUCTION 
Mutations in BRAF at position 600 from valine (V) to glutamic acid (E) occur in 10% of 
colorectal cancers (CRC). BRAFV600E mutations, which account for more than 80% of all 
BRAF mutations (1), lead to sustained MAPK signalling and are associated with poor 
survival and drug resistance (2, 3). Trials investigating the effect of BRAF inhibition given as 
monotherapy have failed in BRAFMT CRC (3). The more recent trials with BRAF/EGFR 
double-therapy or BRAF/MEK/EGFR triple-therapy have shown some increased response 
rates but at the cost of increased toxicity (4, 5). 
The endoplasmic reticulum (ER) is recognized as a major site for protein synthesis/folding 
(6). Increased protein synthesis/misfolding rates that exceed the capacity of protein 
chaperones contribute to the development of ER stress. ER stress is sensed by 3 upstream 
transmembrane proteins, Inositol-Requiring Protein-1 (IRE1), Protein kinase RNA-like ER 
Kinase (PERK) and Activating Transcription Factor-6 (ATF6). Under basal conditions, the 
ER chaperone GRP78 constitutively binds to the three sensors, thus preventing their 
activation. Upon induction of ER stress, sequestration of GRP78 by unfolded proteins results 
in activation of the ER-specific unfolded protein response (UPR), which attempts to reduce 
protein load on the ER and increases its folding capacity. PERK and IRE1α become 
activated following dimerization and auto-phosphorylation (7, 8). Dissociation of GRP78 from 
ATF6 results in translocation of the receptor to the Golgi where it is cleaved by SP1 and SP2 
proteases into an active transcription factor (9). Unresolved ER stress can lead to apoptosis 
through upregulation of the pro-apoptotic transcription factor CHOP, resulting in 
downregulation of the anti-apoptotic protein BCL-2 and upregulation of pro-apoptotic 
proteins such as DR5 and the BH3-only proteins PUMA, NOXA and BIM (10-12).  
In this study, we have used publicly available microarray datasets from CRC patients to 
identify novel pathways associated with the BRAFMT subgroup with the poorest outcome. 
RNAi, cellular and mechanistic assays and xenograft studies indicate that inducers of acute 
ER stress can be a novel treatment strategy for poor prognostic BRAFMT CRC.  
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MATERIALS AND METHODS 
Materials 
Carfilzomib, ACY-1215 and trametinib were purchased from SelleckChem (Suffolk, UK), 
AZD6244 (13) from AstraZeneca (Macclesfield, UK) and Z-VAD-FMK (14) from Calbiochem 
(Hertfordshire, UK). HA15 was generated in house (15). HA15 was synthesised from 
commercial N-(4-(3-aminophenyl)thiazol-2-yl)acetamide and commercial dansyl chloride, 
according to the literature (WO2014/072486). siRNAs targeting Caspase-8, Caspase-9, 
HSPA5 and CHOP were purchased from Qiagen (Crawley, UK) and Invitrogen respectively. 
The ON-Targetplus siRNA library was obtained from Dharmacon (Lafayette, USA). The 
BRAFV600E plasmid was a gift from Prof. Marais (London, UK)(16). 
 
Cell culture 
Authentication and culture of LIM2405, HT-29, VACO432/VT1, RKO, COLO205, COLO320 
and CACO-2 CRC cells have previously been described (17, 18). All cells were passaged for 
a maximum of 2 months, after which new seed stocks were thawed. LIM2405 cells were a 
gift from Dr. Whitehead (Vanderbilt University, Nashville, TN) in 2010 (19). VACO432, VT1 
and RKO were provided by Prof. Vogelstein (Johns Hopkins University School of Medicine, 
Baltimore) in 2012. HT-29 (2001), CACO-2 (2005), COLO205 (2012) and COLO320 (2012) 
cells were obtained from the American Type Culture Collection (Authentication by short 
tandem repeat profiling/karyotyping/isoenzyme analysis). DiFi cells were obtained from Dr. 
Montagut (Barcelona, Spain)(20). 
 
Western blotting 
Western blotting has previously been described (18). Anti-pEIF2αS51, anti-EIF2α, anti-ATF4, 
anti-GRP78, anti-IRE1α, anti-acetylated-α-tubulin, anti-BCL2, anti-BCLXL, anti-PUMA, anti-
BID, anti-BIM (Cell Signaling Technology, Beverly, MA, USA) and anti-pIRE1αS724 (Abcam, 
Cambridge) were used in conjunction with a HRP-conjugated anti-rabbit secondary antibody 
(Amersham, Buckinghamshire, UK). Anti-caspase-8 (12F5; Alexis, San Diego, CA, USA), 
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anti-CHOP (Cell Signaling Technology), anti-ATF6 (Abcam), anti-MCL1 (BD pharmingen, 
Oxford, UK) and anti-NOXA (Abcam) mouse monoclonal antibodies were used in 
conjunction with a horseradish peroxidase–conjugated anti-mouse secondary antibody 
(Amersham).  
 
Flow cytometry  
Apoptosis was evaluated using propidium iodide (PI) staining to determine the percentage of 
cells with DNA content <2N (18). For annexin/PI analysis, cells were harvested and 
analysed according to the manufacturer’s instructions (BD Biosciences).  
 
Caspase activity assays 
Caspase-8 or caspase-3/7-GLO reagents (25l) (Promega, Southampton, UK) were 
incubated with 5g of protein lysate diluted in cell culture medium in a total volume of 50l 
for 45 minutes at room temperature. Luciferase activity was measured using a luminometer. 
 
MTT assays 
Cell viability was determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) (18).  
 
Fluorescence microscopy to assess aggregated protein cargo 
The PROTEOSTAT® Aggresome Detection Kit (Enzo Life Sciences LTD, UK) was used to 
detect aggregated protein cargo, according to the manufacturer’s instructions. Images were 
obtained using the Leica SP5 confocal microscope. 
 
 
 
 
 
 
7 
 
Nascent protein synthesis labelling 
Click-iT L-homopropargylglycine (HPG) Alexa Fluor 488 Protein Synthesis Kit (ThermoFisher 
Scientific) was used to label newly synthesized protein following the manufacturer's protocol. 
Detailed methodology can be found in the supplementary methods.  
 
Real-time reverse transcription-PCR analysis 
Q-PCR analysis was performed using the LightCycler® 480 probes master mix (LightCycler® 
480II, Roche).  
 
siRNA transfections 
siRNA transfections were carried out using Hiperfect (Qiagen) as previously described (18). 
 
Data analysis. 
Generation of gene lists. Initial data analysis was carried out using the R Statistical Package 
(version 3.2.1). The data used in this study was obtained from 566 Affymetrix U133 Plus 2.0 
CRC patient transcriptional profiles accessed through the NCBI GEO accession number 
GSE39582 (21) (discovery data set) and from the 359 Almac stage II CRC DSA CRC patient 
transcriptional profiles, available in the ArrayExpress database (E-MTAB-863/E-MTAB-864) 
(Fig. S1). BRAFV600E mutational status within GSE39582 was assessed by allelic 
discrimination using TaqMan probes (21). Mutational data for BRAF was unavailable for the 
Almac dataset, and we used a highly specific classifier to produce a BRAFMT surrogate 
status (Supplementary Methods). Within the untreated stage II/III GSE39582 and the stage II 
E-MTAB-863/E-MTAB-864 datasets, 31 and 26 patients were identified as BRAFMT 
respectively. A genelist was created of those genes that were differentially expressed 
between poor and good prognostic BRAFMT CRC subgroups, as described further in the 
Supplementary Methods. 
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Pathway Analysis. This was carried out using Ingenuity Pathway Analysis (IPA; Qiagen 
Bioinformatics), using the gene lists differentially expressed between poor and good 
prognostic BRAFMT CRC patients.  
 
In vivo study. In vivo studies were conducted as previously described using 6-8-week-old, 
female BALB/c nude mice (Envigo, UK) (18). In the initial tolerability study, 3 healthy mice 
received ACY-1215 30mg/kg/day IP (Day 1-Day 5 and Day 8-Day 12) alone or in 
combination with Carfilzomib 6mg/kg IP (Day 1/Day 3/Day 5/Day 8/Day 10/Day 12). In the 
efficacy study, ACY-1215 30mg/kg/day IP alone or with Carfilzomib 6mg/kg 3/week IP was 
administered to BALB/c nude mice with VACO432 tumours. Each treatment group contained 
7 animals. Mice were sacrificed and tumours were excised on day 15. All animal 
experiments were carried out according to UKCCCR guidelines under licence PPL2704. In 
vivo experiments were carried out in accordance with the Animals (Scientific Procedures) 
Act, 1986, and approved by the Department of Health, Social Services and Public Safety, 
Northern Ireland. 
 
Statistical analysis 
Student’s t-tests and 2-way ANOVA were calculated using the GraphPad software (Prism5). 
2-way ANOVA test was used to determine the significance of change in levels of apoptosis 
between different treatment groups. Significant changes had p-values <0.05 (* p<0.05; ** 
p<0.01; *** p<0.001; ns not significant). The nature of the interaction between carfilzomib 
and ACY-1215 was determined using the method of Chou and Talalay (18). 
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RESULTS 
Pathway analysis of genelists underpinning poor prognostic BRAFMT CRC. In order to 
identify novel pathways associated with the BRAFMT CRC subgroup with the poorest 
outcome, we generated differentially expressed gene lists between poor and good 
prognostic stage II/III BRAFMT CRC tumours, using the publicly available transcriptionally 
profiled GSE39582 CRC dataset (1.3-fold cut-off; p < 0.05) (Fig. S1)(21). To identify 
pathways that are deregulated in poor prognostic BRAFMT CRC, pathway analyses were 
carried out using both the significantly up-regulated and down-regulated genes in the poor 
prognostic BRAFMT subgroup compared to the good prognostic BRAFMT subgroup (Table 
S1 and Table S2). These results showed that cholesterol biosynthesis, the 
geranylgeranyldiphosphate biosynthesis and mevalonate pathway, G-protein coupled 
receptor signalling and the unfolded protein response (UPR), were the top 5 pathways 
identified from the significantly upregulated gene list in poor prognostic BRAFMT CRC 
(Table S1).  
 
We also identified the UPR as a pathway associated with the BRAFMT subgroup with poor 
outcome, using a second untreated stage II CRC dataset (E-MTAB-863 and E-MTAB-864) 
(Fig. S1). In this study, high-risk patients were previously defined as those with metastatic 
cancer recurrence within 5 years of primary surgery (22). We generated differentially 
expressed gene lists between poor and good prognostic stage II BRAFMT CRC tumours (2-
fold cut-off; p < 0.05) (Fig. S1). IPA analysis, using the significant differential gene list 
between poor and good prognostic stage II BRAFMT CRC, revealed that the UPR was 
significantly associated with the poor prognostic BRAFMT subgroup (Table S3). 
 
GRP78: a key regulator of viability in BRAFMT CRC cells. To identify key functional 
genes/targets for BRAFMT CRC, we used an RNAi screening approach targeting proteins 
that lie at nodal points in the top 20 cancer cell specific pathways identified from the 
significant up-regulated gene list in poor prognostic stage II/III BRAFMT CRC (GSE39582; 
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Table S1). The effect of down-regulating each of these proteins on cell viability was tested in 
the BRAFMT VACO432, RKO, LIM2405 and HT-29 CRC cells, using an ON-Targetplus 
siRNA library against 19 targets (Table S4). Notably, only 1/19 siRNAs had a significant 
inhibitory effect on survival in all 4 BRAFMT cell line models, and this was HSPA5, the gene 
encoding the master regulator of UPR, GRP78 (Table S4; Fig. 1A). This was confirmed 
using additional siRNA sequences against HSPA5 (Fig. S2A). These results are the first to 
demonstrate the importance of GRP78 and the UPR as a potential novel target for BRAFMT 
CRC with poor clinical outcome.  
 
GRP78 inhibition induces ER stress and apoptosis in BRAFMT CRC cells. Based on 
the results from the RNAi screen, we next assessed the involvement of GRP78 and the UPR 
in regulating survival of BRAFMT CRC cells. We used a small molecule inhibitor against 
GRP78, HA15 (15), and the BRAFMT VACO432 CRC cell line, and its isogenic VT1 clone 
with a disrupted BRAFV600E allele (Fig. 1B) (23). A previous study in melanoma has shown 
that HA15 induces dissociation of GRP78 from PERK, IRE1α and ATF6 complexes. 
Treatment with HA15 for 24h resulted in phosphorylation of Serine 51 of EIF2α and 
increases in ATF4 and CHOP, and this was associated with apoptosis induction as indicated 
by PARP cleavage, caspase-9 cleavage and increased caspase-3/7 activity in the BRAFMT 
VACO432 cell line but not in the WT VT1 clone (Fig. 1B, Fig. S2B). Increased 
phosphorylation of IRE1α on Ser724 and ATF6 cleavage were also observed 48h following 
treatment with HA15 in the BRAFMT cells. Similar results were obtained in the BRAFMT HT-
29 cell line, but not in the BRAFWT DiFi, CACO-2 and COLO320 CRC cell line models (Fig. 
1C; Fig. S2C, S2D). Treatment with HA15 also resulted in significant reduction in cell viability 
in the panel of BRAFMT CRC cells (Fig. 1C). As expected, treatment of BRAFMT cells with 
the pan-caspase inhibitor Z-VAD-FMK, abolished the effect of HA15 on PARP cleavage; 
however importantly, caspase inhibition failed to prevent increased IRE1 phosphorylation 
and induction of ATF4 and CHOP, indicating that ER stress activation is upstream of 
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apoptosis induction (Fig. S2C). Collectively, these data indicate that GRP78 inhibition 
induces ER stress and apoptosis in BRAFMT CRC. 
 
In order to define the relative importance of the extrinsic and intrinsic apoptotic pathways in 
mediating HA15-induced apoptosis, we used siRNA specifically directed against caspase-8 
(extrinsic pathway) or caspase-9 (intrinsic pathway) (Fig. 1B). Apoptotic cell death (PARP 
and caspase 3 cleavage) following HA15 treatment was completely abrogated following 
caspase-8 silencing. In addition, the increased caspase-9 p35/37 cleavage products 
(indicative of activation of the intrinsic cell death pathway) that were observed following 
HA15 treatment, were also completely abrogated following caspase-8 silencing. In contrast, 
caspase-9 silencing resulted only in a partial rescue of the PARP cleavage observed 
following HA15 treatment. This suggests that the cell death induced by HA15 proceeds via a 
caspase-8-mediated activation of the caspase-9-dependent intrinsic apoptotic pathway (24). 
To investigate the mechanism of apoptosis further, we assessed expression levels of pro- 
and anti-apoptotic proteins following HA15 treatment in the BRAFMT VACO432 cell line and 
its isogenic VT1 clone (Fig. 1C). Notably, expression of the BH3-only proteins NOXA and 
PUMA, which control the intrinsic cell death pathway, and the death receptor DR5, which 
activates the extrinsic apoptotic pathway, were markedly up-regulated, whereas expression 
of anti-apoptotic BCL-2 family members BCL-2 and MCL-1 were downregulated following 
treatment with HA15 in the BRAFMT VACO432 cell line (Fig. 1C). No changes in DR4 
expression levels were observed following treatment with HA15 treatment (Fig. S2E). Similar 
results were obtained in the BRAFMT HT-29 cell line. CHOP promotes both the transcription 
of DR5 (25) and PUMA (26) and the downregulation of BCL-2 expression (27) contributing to 
the induction of apoptosis. In order to determine whether the ER stress induced by HA15 is 
responsible for apoptosis, we used siRNA against DDIT3 (gene encoding CHOP), a gene 
that mediates ER-stress-induced apoptosis (Fig. 1D). Notably, CHOP silencing abrogated 
HA15-induced PUMA levels and downregulated MCL-1 levels, and decreased HA15-induced 
PARP and caspase-3 cleavage in BRAFMT CRC cells, indicating that the ER stress-
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mediated activation of CHOP is responsible for HA15-induced cell death. Silencing of CHOP 
also partially reversed the decreased cell viability following HA15 treatment in BRAFMT CRC 
cells (Fig. 1D). 
 
Oncogenic BRAF and MEK/ERK trigger increased protein translation, ER stress and 
sensitivity to the ER stress activator HA15. MEK/ERK pathway activation has been 
shown to enhance protein translation/synthesis via phosphorylation of the translation initiator 
eIF4E, thereby exceeding ER protein folding capacity and resulting in ER stress (28). 
Consistent with this, we found marked increased basal levels of peIF4ES209 (Fig. 2A, left) and 
nascent protein production (Fig. 2A, middle) in the BRAFMT VACO432 cell line with 
activated MEK1/2-ERK1/2 pathway, compared to its WT clone (VT1). In addition, constitutive 
levels of the ER stress proteins ATF4, CHOP and the active (spliced) form of XBP1 (sXBP1), 
(indicators of activation of the PERK and IRE1α UPR branches) were also higher in the 
BRAFMT VACO432 cell line, compared to its WT clone (Fig. 2A, right). DDIT3 and ATF4 
mRNA levels were also higher in the VACO432 cell line compared to the VT1 clone (Fig. 2A, 
right). 
 
In order to further investigate the relative importance of the BRAF/MEK pathway in 
regulating sensitivity to the ER stress activator HA15, we used the MEK1/2 inhibitor 
AZD6244. Treatment of BRAFMT cells with AZD6244 potently inhibited peIF4ES209 levels 
(Fig. 2A, left), decreased nascent protein production (Fig. 2B, right) and resulted in a potent 
reduction in basal ATF4 and CHOP levels (Fig. 2B, left). Importantly, AZD6244 treatment 
also resulted in a potent downregulation in HA15-induced ATF4 and CHOP levels and this 
was associated with decreased levels of apoptosis induction following HA15 treatment (Fig. 
2C). Similar results were obtained with the MEK1/2 inhibitor trametinib (Fig. S2F and S2G). 
Moreover, calculation of combination index (CI) values confirmed antagonism between 
trametinib and HA15 in the BRAFMT HT-29 cell line (Fig. S2G). Collectively, these data 
would suggest that oncogenic BRAF and activated MEK1/2-ERK1/2 signalling results in 
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enhanced protein synthesis and chronic ER stress, rendering BRAFMT CRC cells 
susceptible to apoptosis following treatment with acute ER stress activators such as HA15. 
 
Combination of the ER stress inducers carfilzomib and ACY-1215 results in apoptosis 
in BRAFMT CRC cells. To test our hypothesis that BRAFMT CRC cells are vulnerable to 
modulation of the UPR, we used two inhibitors of protein degradation pathways: the 
proteasomal inhibitor Carfilzomib (CFZ) (29) and the aggresome inhibitor ACY-1215 
(HDAC6-selective inhibitor) (30). These compounds are in clinical development and have 
been found to result in overload of misfolded/damaged proteins and ER stress. Initially, we 
evaluated the effects of CFZ and ACY-1215 on viability of the parental BRAFMT VACO432 
CRC cell line and its isogenic VT1 clone, and a panel of BRAFMT (LIM2405, HT-29, 
COLO205, RKO) and WT (CACO-2, COLO320 and DiFi) CRC cells. Sensitivity to both CFZ 
and ACY-1215 was markedly higher in the BRAFMT VACO432 cell line (5.9nM±2.3 and 
1.36M±0.52 respectively) compared to its WT clone (18.46nM±2.9 and 9.63M±2.95 
respectively), and this was associated with increased apoptosis as determined by PARP 
cleavage and increased sub-G1 levels in the VACO432 cells compared to the VT1 cells (Fig. 
3A, 3B; Fig. S3A). ACY-1215 caused an increase in acetylation of α-tubulin, a marker of 
HDAC6 inhibition. There was however no clear pattern of increased sensitivity to CFZ or 
ACY-1215 in the panel of non-matched BRAFMT and WT CRC cells (Fig. S3A).  
 
Next, we investigated the effects of combination treatment of CFZ with ACY-1215 on survival 
of BRAFMT/WT CRC cells. Combined treatment of CFZ with ACY-1215 resulted in potent 
increases in apoptosis as indicated by increased PARP cleavage and caspase-3 processing, 
caspase-8 and -3/7 activity assays and flow cytometry in the BRAFMT VACO432 cell line 
but not the WT VT1 clone (Fig. 3B; S3B and S3C). In addition, transient overexpression of 
BRAFV600E led to increased CHOP expression levels and was associated with increased 
PARP processing and caspase 3/7 activity in response to combined ACY-1215/CFZ 
treatment in the BRAFWT VT1 cells (Fig. 3B). Importantly, similar results were obtained in a 
 
 
14 
 
wider panel of BRAFMT (HT-29, LIM2405, RKO, COLO205), but not BRAFWT CRC cell line 
models (COLO320, CACO-2, DiFi cells) (Fig. 3C, 3D and S3C). Caspase-dependent 
apoptosis following CFZ/ACY-1215 treatment was assessed using the pan-caspase inhibitor 
Z-VAD-FMK, which attenuated apoptosis (Fig. S4A). Silencing of caspase-9 partially 
reduced PARP and C3 cleavage following CFZ/ACY-1215 co-treatment, suggesting a 
predominant role of the intrinsic apoptotic pathway in regulating CFZ/ACY-1215-induced cell 
death (Fig. S4B). Calculation of combination index (CI) values confirmed strong synergy 
between CFZ and ACY-1215 in all BRAFMT CRC cells (Fig. S4C). Taken together, these 
data would indicate that BRAFMT CRC cells show increased sensitivity to dual targeting of 
protein degradation pathways.  
 
Combination of CFZ and ACY-1215 results in accumulation of misfolded/unfolded 
proteins and ER stress in BRAFMT CRC cells. To investigate the mechanism underlying 
the observed synergy between CFZ and ACY-1215, we used the PROTEOSTAT® dye, a 
fluorescent dye that facilitates the detection of aggregated protein cargoes within 
aggresomes and other inclusion bodies (31). Treatment of the BRAFMT VACO432 cells with 
combined CFZ/ACY-1215 resulted in a marked accumulation of aggregated proteins, 
compared to the effect of either agent alone (Fig. 4A). Aggregation of proteins following 
combined CFZ/ACY-1215 treatment was markedly less induced in its BRAFWT clone. 
Moreover, the combination of ACY-1215 with CFZ increased the accumulation of 
ubiquitinated proteins, in particular in the BRAFMT VACO432, COLO205 and RKO cells, but 
not in the BRAFWT VT1 and DiFi cells (Fig. 4B; Fig. S5).  
 
Proteasomal and aggresome inhibition has been shown to induce ER stress (32, 33). In 
order to explore the role of the UPR in mediating apoptosis following combined CFZ/ACY-
1215 treatment, we assessed expression and phosphorylation levels of the pro-apoptotic 
UPR proteins CHOP and JNK, 24h following treatment with CFZ and ACY-1215 (Fig. 5A, 
5B). We found marked increased expression levels of CHOP in all BRAFMT but not 
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BRAFWT cells following combined CFZ/ACY-1215 treatment. In addition, increased 
pJNKT183/Y185 was also observed in CFZ/ACY-1215-treated BRAFMT HT-29, LIM-2405, RKO 
and COLO205 cells (Fig. 5A). We also determined the kinetics of activation of the PERK, 
IRE1α and ATF6 branches of the UPR following co-treatment with CFZ/ACY-1215 and found 
marked increases in ATF4 and CHOP levels, as early as 6h and 12-24h respectively 
following co-treatment with CFZ/ACY-1215 in all BRAFMT CRC cells (Fig. 5C). Increased 
IRE1α and JNK activity was observed 6h and 12-24h respectively following treatment with 
CFZ/ACY-1215, whereas ATF6 cleavage occurred 12-24h following treatment with 
CFZ/ACY-1215, in particular in the BRAFMT COLO205 cells (Fig. 5C). 
 
CHOP is important in regulating CFZ/ACY-1215-induced cell death in BRAFMT CRC  
To investigate whether activation of the UPR induced by combined CFZ/ACY-1215 
treatment is responsible for the observed apoptosis, we used siRNA specifically directed 
against CHOP. Notably, silencing of CHOP completely abrogated the synergistic induction in 
caspase-3 and PARP cleavage following combined CFZ/ACY-1215 treatment in BRAFMT 
CRC cells. Collectively, these results would suggest a causal role for the UPR pathway in 
the cell death following combination of CFZ with ACY-1215 in BRAFMT CRC (Fig. 5D).  
 
ACY-1215 in combination with CFZ inhibits the growth of BRAFMT xenograft models.  
To extend these in vitro findings, we next assessed the therapeutic efficacy of combined 
ACY-1215 and CFZ in the BRAFMT VACO432 xenograft model. ACY-1215 and CFZ were 
administered at 30mg/kg/day IP and Carfilzomib 6mg/kg 3/week IP, the maximum tolerable 
dose determined in our initial dose escalation study (Fig. S6A). Although both CFZ and ACY-
1215 slowed tumour growth, the CFZ/ACY-1215 combination led to a supra-additive 
reduction in growth in VACO432 BRAFMT xenograft model (Fig. 6A, left panel). 
Furthermore, combined CFZ/ACY-1215 treatment significantly reduced tumour weight, 
compared to the effect of each treatment alone (Fig. 6A, middle panel). Furthermore, 
caspase-3 cleavage was observed in the VACO432 tumours following treatment with CFZ in 
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combination with ACY-1215, indicative of apoptosis induction (Fig. 6A, right panel). The 
combined treatment was also tolerated in this efficacy study, with only minor weight loss 
occurring in both vehicle and combination arms (5.96% and 6.1% respectively) (Fig. S6B). 
These findings indicate that dual targeting of protein degradation pathways using CFZ and 
ACY-1215 may be highly effective to treat BRAFMT CRC.  
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DISCUSSION 
A number of research groups have identified 3-6 molecular subtypes within stage II/III CRC, 
using gene expression profiles and unsupervised classification (21). Recently, the CRC 
Subtyping Consortium (CRCSC) has integrated these independent classification systems 
into 4 Consensus Molecular Subtypes (CMS 1-4) (34). More than 70% of BRAFV600E mutant 
cases were assigned to CMS 1 (with strong association with MSI), whereas 17% and 6% of 
mutant BRAF patients were classified into CMS 4 (cancers which display mesenchymal 
features with high stromal infiltration) and CMS 3 (cancers with metabolic deregulation) 
respectively. In order to better characterize the heterogeneity within BRAFMT CRC tumours, 
a recent study performed unsupervised classification of gene expression profiles derived 
from treated/untreated stage I/II/III BRAFMT CRC and identified 2 distinct subgroups: BM1, 
associated with high KRAS/mTOR/AKT/eEBP1, EMT activation and immune infiltration and 
BM2 which displays cell-cycle checkpoint dysregulation (35). In this study, we performed for 
the first time supervised clustering of BRAFMT gene expression profiles, to identify novel 
pathways and targets associated with the BRAFMT subgroup with poorest outcome. These 
studies identified a number of biological processes that were deregulated in the BRAFMT 
subgroup with poorest outcome, including the UPR. 
 
Activation of different arms of the UPR have been reported in several solid tumours (36), as 
well as haematological malignancies (37) and have been identified as a poor prognostic 
marker in these tumours. In CRC, activation of IRE1α-XBP1 UPR branch has been 
associated with increased proliferation, invasion and poor prognosis (38). Using a siRNA 
screening approach and multiple BRAFMT cell line models, we identified that GRP78, the 
master regulator of the UPR, was important for maintaining the viability of BRAFMT CRC 
cells. Moreover, using an inhibitor of GRP78, which dissociates GRP78 from PERK, IRE1α 
and ATF6 (15), the differential dependency of BRAFMT and WT cells on GRP78 for survival 
was further demonstrated. GRP78 belongs to the heat shock protein 70 (HSP70) family, 
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facilitates protein folding, targets misfolded proteins for proteasomal degradation and 
regulates ER stress (39). Overexpression of GRP78 has been observed in many tumours, 
including CRC (40) and has been associated with resistance to chemotherapy (41). The 
relative overexpression of GRP78 highlights the potential for exploitation of GRP78 as a 
therapeutic target in CRC. Increased ERK signalling has been shown to activate protein 
synthesis, which may result in an imbalance between the ER protein load and folding 
capacity, resulting in chronic ER stress (42). Indeed, we found that BRAF and MEK 
regulated levels of eIF4ES209, nascent protein synthesis and ATF4/CHOP and sXBP1 
expression levels in BRAFMT CRC cells. In contrast to a study from Jiang et al. in BRAFMT 
melanoma (43), our study showed that MEK inhibition decreases chronic ER stress and 
protects BRAFMT cells against apoptosis induced by acute ER stress. Furthermore, 
inhibition of CHOP, a transcription factor that controls the development of programmed cell 
death in response to acute ER stress (44), prevented apoptosis induced by HA15, indicating 
the causal role of acute ER stress in HA15-induced apoptosis in BRAFMT CRC. These data 
are the first to show that BRAFMT CRC is addicted to the UPR for survival and that UPR 
activators, such as HA15, result in acute ER stress and apoptosis in BRAFMT CRC. 
However, to date there are no existing treatments in routine clinical use that specifically 
target GRP78. 
 
Proteasome inhibitors (PI) represent a class of agents that exert their anti-cancer effects by 
inducing accumulation of misfolded poly-ubiquitinated proteins and ER stress (32). There are 
many PI at various stages of clinical development and, to date, bortezomib, carfilzomib and 
ixazomib have been approved by the Federal Drugs Administration for use in multiple 
myeloma (45, 46). In contrast to bortezomib, carfilzomib is an irreversible inhibitor, 
characterized by a preferential inhibitory potency against the chymotrypsin-like activity of the 
proteasome, with potent and persistent inhibition (47). Contrary to a previous study in 
BRAFMT CRC (48), we did not find increased sensitivity to carfilzomib across the BRAFMT 
CRC cell line panel, compared to our BRAFWT cells. Selective targeting of HDAC6, a class 
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IIb Histone Deacetylase, results in acetylation of α-tubulin which disrupts binding of the 
HDAC6-tubulin-dynein motor complex to misfolded protein aggregates and inhibits 
aggresome-mediated protein degradation, leading to ER stress (33). In addition, a recent 
study has shown that HDAC6 inhibition results in acetylation of GRP78 and disruption of the 
GRP78/PERK complex (49). We found that dual targeting of protein degradation pathways, 
using CFZ and ACY-1215, resulted in marked accumulation of ubiquitinated protein 
aggregates, caspase-dependent apoptosis and strong synergy in BRAFMT CRC cells, but 
not BRAFWT cells. Mechanistically, we found that combined CFZ/ACY-1215 treatment 
resulted in marked increased expression of pEIF2αS51/ATF4 and pIRE1αS724/pJNKT183/Y185, 
culminating in increased levels of the pro-apoptotic CHOP. Furthermore, we found that 
siCHOP protected BRAFMT CRC from apoptosis following CFZ/ACY-1215 treatment, 
demonstrating the causal role of the UPR in increased apoptosis following combined 
CFZ/ACY-1215 treatment in BRAFMT CRC. Importantly, we also demonstrated that CFZ in 
conjunction with ACY-1215 was highly effective at blocking the growth and inducing 
apoptosis in a BRAFMT CRC xenograft. 
 
Combinations of proteasome and HDAC inhibitors have been translated into clinical trials on 
the basis of dual inhibition of the aggresome and proteasome pathway, in particular in 
haematological disease. The VANTAGE 095 phase IIb trial of vorinostat (MK-0683) and 
bortezomib showed a signal of activity in patients with relapsed/refractory multiple myeloma 
(50). More recent studies using the selective HDAC6 inhibitor ACY-1215 and bortezomib or 
the more potent proteasome inhibitor CFZ have shown strong synergy in preclinical models 
of lymphoma and multiple myeloma respectively (49, 51). This is the first study showing that 
dual aggresome/proteasome inhibition could be a promising treatment strategy for BRAFMT 
CRC patients. This study does not exclude that other poor prognostic subtypes eg. 
subgroups of BRAFWT/RASMT CRC may also be associated with chronic ER stress and 
therefore could potentially benefit from acute ER stress inducers.  
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In conclusion, using a systems biology approach, we have identified the UPR as an 
important, novel and druggable target for the BRAFMT CRC subgroup with poorest clinical 
outcome. We have shown that BRAFMT CRC induces chronic ER stress, is addicted to the 
UPR for survival and that UPR activators result in acute ER stress and apoptosis in 
BRAFMT CRC (Fig. 6B). From a clinical perspective, the substantial tumour growth inhibition 
observed in our xenograft study support the evaluation of UPR activators (eg. 
aggresome/proteasome co-inhibition or more specific ATF4/CHOP activators (52)) in clinical 
trials for patients with metastatic BRAFMT CRC.  
  
 
 
21 
 
ACKNOWLEDGMENTS 
We thank Enzo Medico, Andrea Bertotti and Dan Longley for providing bioinformatic and in 
vivo support respectively.  
  
 
 
22 
 
REFERENCES 
1. Pakneshan S, Salajegheh A, Smith RA, Lam AK. Clinicopathological relevance of 
BRAF mutations in human cancer. Pathology. 2013;45:346-56. 
2. Popovici V, Budinska E, Tejpar S, Weinrich S, Estrella H, Hodgson G, et al. 
Identification of a poor-prognosis BRAF-mutant-like population of patients with colon 
cancer. J Clin Oncol. 2012;30:1288-95. 
3. Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Lee RJ, et al. PLX4032 in 
metastatic colorectal cancer patients with mutant BRAF tumors. J Clin Oncol 
2010;28: 15s (suppl; abstr 3534). 
4. Yaeger R, Cercek A, O'Reilly EM, Reidy DL, Kemeny N, Wolinsky T, et al. Pilot trial 
of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer 
patients. Clin Cancer Res. 2015;21:1313-20. 
5. Atreya CE, Van Cutsem E, Bendell JC, Andre T, Schellens JH, Gordon MS, et al. 
Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), 
and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E 
mutated (BRAFm) metastatic colorectal cancer (mCRC). J Clin Oncol 33, 2015 
(suppl; abstr 103). 
6. Schwarz DS, Blower MD. The endoplasmic reticulum: structure, function and 
response to cellular signaling. Cell Mol Life Sci. 2016;73:79-94. 
7. Harding HP, Zhang Y, Bertolotti A, Zeng H, Ron D. Perk is essential for translational 
regulation and cell survival during the unfolded protein response. Molecular cell. 
2000;5:897-904. 
8. Liu CY, Xu Z, Kaufman RJ. Structure and intermolecular interactions of the luminal 
dimerization domain of human IRE1alpha. J Biol Chem. 2003;278:17680-7. 
9. Shen J, Chen X, Hendershot L, Prywes R. ER stress regulation of ATF6 localization 
by dissociation of BiP/GRP78 binding and unmasking of Golgi localization signals. 
Developmental cell. 2002;3:99-111. 
10. Tabas I, Ron D. Integrating the mechanisms of apoptosis induced by endoplasmic 
reticulum stress. Nat Cell Biol. 2011;13:184-90. 
11. Puthalakath H, O'Reilly LA, Gunn P, Lee L, Kelly PN, Huntington ND, et al. ER stress 
triggers apoptosis by activating BH3-only protein Bim. Cell. 2007;129:1337-49. 
12. Yamaguchi H, Wang HG. CHOP is involved in endoplasmic reticulum stress-induced 
apoptosis by enhancing DR5 expression in human carcinoma cells. J Biol Chem. 
2004;279:45495-502. 
13. Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ, et al. Biological 
characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-
activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res. 2007;13:1576-83. 
14. Berger AB, Witte MD, Denault JB, Sadaghiani AM, Sexton KM, Salvesen GS, et al. 
Identification of early intermediates of caspase activation using selective inhibitors 
and activity-based probes. Molecular cell. 2006;23:509-21. 
15. Cerezo M, Lehraiki A, Millet A, Rouaud F, Plaisant M, Jaune E, et al. Compounds 
Triggering ER Stress Exert Anti-Melanoma Effects and Overcome BRAF Inhibitor 
Resistance. Cancer Cell. 2016;29:805-19. 
16. Marais R, Light Y, Paterson HF, Mason CS, Marshall CJ. Differential regulation of 
Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J Biol Chem. 
1997;272:4378-83. 
17. Van Schaeybroeck S, Kyula JN, Fenton A, Fenning CS, Sasazuki T, Shirasawa S, et 
al. Oncogenic Kras promotes chemotherapy-induced growth factor shedding via 
ADAM17. Cancer Res. 2011;71:1071-80. 
18. Van Schaeybroeck S, Kalimutho M, Dunne PD, Carson R, Allen W, Jithesh PV, et al. 
ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors 
in KRAS mutant colorectal cancer. Cell reports. 2014;7:1940-55. 
 
 
23 
 
19. Whitehead RH, Zhang HH, Hayward IP. Retention of tissue-specific phenotype in a 
panel of colon carcinoma cell lines: relationship to clinical correlates. Immunol Cell 
Biol. 1992;70 ( Pt 4):227-36. 
20. Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M, et al. 
Identification of a mutation in the extracellular domain of the Epidermal Growth 
Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med. 
2012;18:221-3. 
21. Marisa L, de Reynies A, Duval A, Selves J, Gaub MP, Vescovo L, et al. Gene 
expression classification of colon cancer into molecular subtypes: characterization, 
validation, and prognostic value. PLoS medicine. 2013;10:e1001453. 
22. Kennedy RD, Bylesjo M, Kerr P, Davison T, Black JM, Kay EW, et al. Development 
and Independent Validation of a Prognostic Assay for Stage II Colon Cancer Using 
Formalin-Fixed Paraffin-Embedded Tissue. J Clin Oncol. 2011; 29:4620-6. 
23. Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, et al. Glucose 
deprivation contributes to the development of KRAS pathway mutations in tumor 
cells. Science. 2009;325:1555-9. 
24. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the 
mitochondrial damage in the Fas pathway of apoptosis. Cell. 1998;94:491-501. 
25. Lu M, Lawrence DA, Marsters S, Acosta-Alvear D, Kimmig P, Mendez AS, et al. 
Opposing unfolded-protein-response signals converge on death receptor 5 to control 
apoptosis. Science. 2014;345:98-101. 
26. Cazanave SC, Elmi NA, Akazawa Y, Bronk SF, Mott JL, Gores GJ. CHOP and AP-1 
cooperatively mediate PUMA expression during lipoapoptosis. Am J Physiol 
Gastrointest Liver Physiol. 2010;299:G236-43. 
27. McCullough KD, Martindale JL, Klotz LO, Aw TY, Holbrook NJ. Gadd153 sensitizes 
cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the 
cellular redox state. Molecular and cellular biology. 2001;21:1249-59. 
28. Hou J, Lam F, Proud C, Wang S. Targeting Mnks for cancer therapy. Oncotarget. 
2012;3:118-31. 
29. Kortuem KM, Stewart AK. Carfilzomib. Blood. 2013;121:893-7. 
30. Santo L, Hideshima T, Kung AL, Tseng JC, Tamang D, Yang M, et al. Preclinical 
activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 
inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood. 
2012;119:2579-89. 
31. Shen D, Coleman J, Chan E, Nicholson TP, Dai L, Sheppard PW, et al. Novel cell- 
and tissue-based assays for detecting misfolded and aggregated protein 
accumulation within aggresomes and inclusion bodies. Cell Biochem Biophys. 
2011;60:173-85. 
32. Obeng EA, Carlson LM, Gutman DM, Harrington WJ, Jr., Lee KP, Boise LH. 
Proteasome inhibitors induce a terminal unfolded protein response in multiple 
myeloma cells. Blood. 2006;107:4907-16. 
33. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP. The deacetylase 
HDAC6 regulates aggresome formation and cell viability in response to misfolded 
protein stress. Cell. 2003;115:727-38. 
34. Guinney J, Dienstmann R, Wang X, de Reynies A, Schlicker A, Soneson C, et al. 
The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21:1350-6. 
35. Barras D, Missiaglia E, Wirapati P, Sieber OM, Jorissen RN, Love C, et al. BRAF 
V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression. Clin Cancer 
Res. 2017;23:104-15. 
36. Penaranda Fajardo NM, Meijer C, Kruyt FA. The endoplasmic reticulum 
stress/unfolded protein response in gliomagenesis, tumor progression and as a 
therapeutic target in glioblastoma. Biochemical pharmacology. 2016;118:1-8. 
37. Chen L, Li Q, She T, Li H, Yue Y, Gao S, et al. IRE1alpha-XBP1 signaling pathway, a 
potential therapeutic target in multiple myeloma. Leuk Res. 2016;49:7-12. 
 
 
24 
 
38. Jin C, Jin Z, Chen NZ, Lu M, Liu CB, Hu WL, et al. Activation of IRE1alpha-XBP1 
pathway induces cell proliferation and invasion in colorectal carcinoma. Biochem 
Biophys Res Commun. 2016;470:75-81. 
39. Lee AS. GRP78 induction in cancer: therapeutic and prognostic implications. Cancer 
Res. 2007;67:3496-9. 
40. Piton N, Wason J, Colasse E, Cornic M, Lemoine F, Le Pessot F, et al. Endoplasmic 
reticulum stress, unfolded protein response and development of colon 
adenocarcinoma. Virchows Arch. 2016;469:145-54. 
41. Mhaidat NM, Alzoubi KH, Almomani N, Khabour OF. Expression of glucose regulated 
protein 78 (GRP78) determines colorectal cancer response to chemotherapy. Cancer 
Biomark. 2015;15:197-203. 
42. Oslowski CM, Urano F. Measuring ER stress and the unfolded protein response 
using mammalian tissue culture system. Methods Enzymol. 2011;490:71-92. 
43. Jiang CC, Chen LH, Gillespie S, Wang YF, Kiejda KA, Zhang XD, et al. Inhibition of 
MEK sensitizes human melanoma cells to endoplasmic reticulum stress-induced 
apoptosis. Cancer Res. 2007;67:9750-61. 
44. Zinszner H, Kuroda M, Wang X, Batchvarova N, Lightfoot RT, Remotti H, et al. 
CHOP is implicated in programmed cell death in response to impaired function of the 
endoplasmic reticulum. Genes & development. 1998;12:982-95. 
45. Teicher BA, Tomaszewski JE. Proteasome inhibitors. Biochemical pharmacology. 
2015;96:1-9. 
46. Shirley M. Ixazomib: First Global Approval. Drugs. 2016;76:405-11. 
47. Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, et al. Potent 
activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome 
pathway, against preclinical models of multiple myeloma. Blood. 2007;110:3281-90. 
48. Zecchin D, Boscaro V, Medico E, Barault L, Martini M, Arena S, et al. BRAF V600E is 
a determinant of sensitivity to proteasome inhibitors. Mol Cancer Ther. 
2013;12:2950-61. 
49. Amengual JE, Johannet P, Lombardo M, Zullo K, Hoehn D, Bhagat G, et al. Dual 
Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-
1215 and Bortezomib Is Synergistic in Lymphoma. Clin Cancer Res. 2015;21:4663-
75. 
50. Siegel DS, Dimopoulos M, Jagannath S, Goldschmidt H, Durrant S, Kaufman JL, et 
al. VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat 
(MK-0683) in Combination With Bortezomib in Patients With Relapsed and 
Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2016;16:329-34 e1. 
51. Mishima Y, Santo L, Eda H, Cirstea D, Nemani N, Yee AJ, et al. Ricolinostat (ACY-
1215) induced inhibition of aggresome formation accelerates carfilzomib-induced 
multiple myeloma cell death. British journal of haematology. 2015;169:423-34. 
52. Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, et al. Discovery 
and clinical introduction of first-in-class imipridone ONC201. Oncotarget. 
2016;7:74380-92. 
 
 
 
 
 
 
 
 
25 
 
FIGURE LEGENDS 
Figure 1. BRAFMT CRC cells are dependent on the UPR for survival. A. Results of the 
siRNA screen. BRAFMT cells were reverse transfected with all stars’ non-targeted siRNA 
sequence and sequence specific siRNA. Cell viability was calculated following 72h 
transfection using the CellTitre-Glo assay. Data for siHSPA5 are shown. Western blotting 
(WB) for GRP78 and PARP following siHSPA5 (HA) for 48h. Full siRNA screen data can be 
found in Table S4. B. Left: PARP, pEIF2αS51, EIF2α, ATF4, CHOP, ATF6, GRP78, 
pIRE1αS724 and IRE1α expression in VACO432 and VT1 cells, following treatment with HA15 
for the indicated time. Right upper: Caspase-3/7 activity levels in VACO432 cells, following 
treatment with HA15. Right lower: VACO432 cells were transfected with scrambled control 
(SC), caspase-8 (siC8) or caspase-9 siRNA (siC9) for 24h and thereafter treated with HA15 
for 24h. Cleaved-PARP, caspase-3, pro-caspase-8 and caspase-9 were determined by WB. 
C. Upper: PARP, BCL-2, BCL-XL, MCL-1, PUMA, NOXA, BID and BIM levels in BRAFMT 
VACO432, HT-29 and BRAFWT VT1 cells following treatment with HA15 for the indicated 
time. Lower left: CRC cells were treated with HA15 for 24h and DR5 cell membrane 
expression assessed by flow cytometry using receptor-specific phycoerythrin-conjugated 
mAbs. Expression was compared with a nonspecific isotype-matched control antibody. 
Lower right: MTT cell viability of BRAFMT cells following 72h treatment with HA15. D. 
Upper: VACO432 cells were transfected with SC or DDIT3 (siCH) siRNA for 24h and 
thereafter treated with HA15 for 24h. Cleaved-PARP, caspase-3, CHOP, PUMA, BCL-2 and 
MCL-1 expression were determined by WB. Lower: MTT cell viability of BRAFMT cells 
transfected with siCH and co-treated with HA15 for 72h. SE=short exposure; LE=long 
exposure. 
 
Figure 2. MEK/ERK trigger sensitivity to the ER stress activator HA15. A. Left: 
BRAFMT VACO432 and LIM2405 and BRAFWT VT1 cells were treated with AZD6244 for 
24h and peIF4ES209, eIF4E, pERK1/2, ERK1/2, pMEK1/2 and MEK1/2 levels determined by 
WB. Middle: Representative image of Click-iT protein synthesis assay in VACO432 and VT1 
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cells. Right: BRAF, ERK1/2, pERK1/2, ATF4, CHOP and sXBP1 basal expression in 
VACO432 and VT1 cells determined by WB and/or real-time PCR. B. Left: ATF4, CHOP, 
sXBP1, GRP78 and ERK1/2 expression following 24h treatment with AZD6244 in BRAFMT 
cells. Right: Representative image of Click-iT protein synthesis assay in VACO432 cells 
following treatment with AZD6244 for 24h. C. PARP, ATF4, CHOP, sXBP1, GRP78 and 
ERK1/2 levels following co-treatment with AZD6244 and HA15 for 24h. Scale bar represents 
20 micrometer. SE=short exposure; LE=long exposure. 
 
Figure 3. Dual targeting of the aggresome and proteasome pathway results in cell 
death in BRAFMT CRC. A. WB analysis of PARP and acetylated-α-tubulin in CRC cells 
following treatment with ACY-1215 or Carfilzomib (CFZ) for 24h. B. Left upper: CRC cells 
were co-treated with ACY-1215 and CFZ for 24h and PARP, cleaved caspase-8 (C8), 
cleaved caspase-3 (C3) and acetylated-α-tubulin determined by WB. Left lower: Annexin 
V/PI flow cytometric analysis of CRC cells following treatment with ACY-1215 and CFZ for 
24h. Right: Expression of BRAF, pMEK1/2, MEK1/2, pERK1/2, ERK1/2, CHOP and PARP 
(upper) and C3/7 activity levels (lower) in VT1 cells transiently transfected with 1µg of 
BRAFV600E expression construct for 12h followed by 24h treatment with ACY-1215, CFZ or 
ACY-1215/CFZ. C. BRAFMT cells were co-treated with ACY-1215 and CFZ for 24h and 
apoptosis determined by WB for PARP, cleaved-C8 and cleaved-C3 (upper) and PI flow 
cytometry (lower). D. BRAF/KRASWT COLO320, CACO-2 and DiFi cells were treated with 
ACY-1215 and Carfilzomib for 24h and PARP, cleaved caspase 8 (p43/41), cleaved caspase 
3, and acetylated α tubulin expression levels determined by WB. BRAFMT VACO432 cells 
were treated with ACY-1215/CFZ for 24h. 
 
Figure 4. Combined aggresome/proteasome inhibition results in accumulation of 
aggregated proteins in BRAFMT CRC cells. A. Protein aggregates in CRC cells, treated 
with ACY-1215, CFZ or combination (Proteostat dye (red), counterstained with Hoechst 
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33342). Scale bar represents 20 micrometer. B. Total levels of ubiquitinated proteins in 
BRAFMT/WT CRC cells, treated with ACY-1215 and CFZ for 12h.  
 
Figure 5. Dual targeting of protein degradation pathways results in acute ER stress 
and apoptosis. A. CRC cells were treated with CFZ alone or combined with ACY-1215 and 
PARP, CHOP, pJNKT183/Y185 and JNK levels determined by WB. B. CRC cells were treated 
with CFZ alone or combined with ACY-1215 for 24h and DDIT3 mRNA levels determined by 
real-time PCR. Relative mRNA expression was calculated using the DDCt method with 
normalisation to -actin and GAPDH. C. PARP and levels of UPR proteins in BRAFMT cells 
following treatment with ACY-1215 and/or CFZ for the indicated times. D. LIM2405 cells 
were transfected with SC or siCH for 24h and thereafter treated with ACY-1215 and CFZ for 
24h. PARP, cleaved-C3 and CHOP expression were determined by WB and/or activity 
assay. 
 
Figure 6. Combined ACY-1215/CFZ treatment results in reduction in growth of 
BRAFMT CRC in vivo. A. Growth rate (left) and tumour weights at day 15 (middle) of 
VACO432 xenografts in BALB/c Nude mice treated with vehicle, ACY-1215, CFZ or in 
combination. Differences in growth were determined using Student’s t-test. WB analysis for 
cleaved-C3 in tumour samples (Right). B. Schematic overview of proposed model. As a 
result of enhanced protein synthesis, BRAFMT CRC tumours induce chronic ER stress, 
resulting in cancer cell survival. ACY-1215/CFZ and HA15 result in acute ER stress, 
increased CHOP expression and apoptosis, through activation of both extrinsic and extrinsic 
cell death pathways. 
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